BNP Paribas Financial Markets Makes New Investment in Ginkgo Bioworks Holdings, Inc. (NYSE:DNA)

BNP Paribas Financial Markets acquired a new position in Ginkgo Bioworks Holdings, Inc. (NYSE:DNA - Free Report) during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund acquired 157,862 shares of the company's stock, valued at approximately $1,287,000. BNP Paribas Financial Markets owned about 0.28% of Ginkgo Bioworks at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Forbes J M & Co. LLP bought a new position in Ginkgo Bioworks during the third quarter valued at approximately $1,019,000. PFG Investments LLC purchased a new stake in Ginkgo Bioworks during the third quarter valued at $1,541,000. Wellington Wealth Strategies LLC. bought a new position in Ginkgo Bioworks in the second quarter valued at about $41,000. Algert Global LLC bought a new stake in shares of Ginkgo Bioworks during the 2nd quarter valued at about $36,000. Finally, Mackenzie Financial Corp purchased a new stake in shares of Ginkgo Bioworks during the 2nd quarter valued at about $251,000. 78.63% of the stock is currently owned by hedge funds and other institutional investors.

Ginkgo Bioworks Stock Performance

Shares of DNA traded up $0.36 during trading hours on Tuesday, reaching $11.06. 1,102,229 shares of the stock traded hands, compared to its average volume of 1,160,538. The company has a market capitalization of $635.43 million, a P/E ratio of -0.85 and a beta of 1.17. The company's 50-day simple moving average is $8.28. Ginkgo Bioworks Holdings, Inc. has a 52-week low of $5.26 and a 52-week high of $75.20.

Analysts Set New Price Targets

A number of analysts have commented on the stock. TD Cowen upped their target price on shares of Ginkgo Bioworks from $3.00 to $10.00 and gave the company a "buy" rating in a report on Friday, September 20th. BTIG Research raised their target price on Ginkgo Bioworks from $0.20 to $7.00 and gave the stock a "sell" rating in a report on Friday, August 23rd. Three analysts have rated the stock with a sell rating, one has given a hold rating and one has given a buy rating to the company's stock. Based on data from MarketBeat.com, the company currently has an average rating of "Hold" and a consensus target price of $4.58.

About Ginkgo Bioworks

Ginkgo Bioworks Holdings, Inc, together with its subsidiaries, develops platform for cell programming in the United States. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. It serves pharma and biotech, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries.